Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...
During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...
Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare ...
Biogen Inc. ( BIIB) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST ...
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback